Menu
About Us
Company Overview
Our Values
Board of Directors
Team
Scientific Advisers
Clinical Advisers
Corporate Directory
Corporate Governance
Pipeline
Clinical Trial
Investor Centre
Welcome
Investor Fact Sheet
ASX Announcements
Reports
Annual Reports
Half Yearly Reports
Quarterly Reports
Top 20 Shareholders
Research Reports
Shareholder Services
Investor FAQs
US Shareholders
Investor Newsletters
Communication
In the News
Presentations
Contact Us
Contact Us
Email Alerts
In the news
Recent Posts
Interim Data from ACCENT Pancreatic Cancer Trial
Dr Chris Burns elected as a Fellow to the Australian Academy of Health and Medical Sciences (AAHMS)
ASX Briefs podcast | Interview with Dr Chris Burns
Recruitment Restarts in Accent Pancreatic Cancer Trial
NBN News Interview
Dr Chris Burns Announced as Co-Recipient of 2024 Prime Minister's Prize for Innovation
Categories
Archive
Company News
Investor Newsletters
Videos
10 Nov 2021
VIDEO | AUSBIZ Amplia's $12M plan; what's next for the Aussie medtech
Read More
10 Nov 2021
VIDEO | Proactive Investors, $12.4m Capital Raise
Read More
08 Nov 2021
$12.4m Capital Raise
Read More
26 Oct 2021
Amplia appoints leading drug developer as Oncology Clinical Advisor
Read More
21 Oct 2021
Switzer Daily | Therapeutics company primed for growth
Read More
07 Oct 2021
MEET THE TEAM | Dr John Lambert, CEO
Read More
04 Oct 2021
VIDEO | Science Advances paper discussed on Proactive
Read More
30 Sep 2021
VIDEO | Amplia featured on Channel 9 News
Read More
30 Sep 2021
BioMelbourne Network | Breakthrough research on pancreatic cancer
Read More
30 Sep 2021
Amplia Therapeutics welcomes Garvan paper highlighting benefits of FAK inhibition in pancreatic cancer models
Read More
30 Sep 2021
Amplia Therapeutics says ‘priming’ a tumour could improve outcomes for patients with pancreatic cancer
Read More
30 Sep 2021
Breakthrough research lowers pancreatic cancer’s resistance to chemo
Read More
30 Sep 2021
New FAK research published in Science Advances
Read More
29 Sep 2021
VIDEO | Proactive Lifesciences Webinar
Read More
27 Sep 2021
Proactive Lifesciences Webinar
Read More
22 Sep 2021
Bioshares | Amplia Therapeutics to Start Two Phase II Studies in 2022
Read More
20 Sep 2021
Proactive | Interview with Dr John Lambert
Read More
26 Jul 2021
Amplia Therapeutics phase 1 results support development of AMP945 in cancer and fibrosis
Read More
26 Jul 2021
Amplia Therapeutics develops new approach to treat cancer and fibrosis
Read More
21 Jul 2021
Amplia Therapeutics returns successful phase one trial results
Read More
1
2
3
4
5
6
